AbbVie’s last stand: How an Icelandic billionaire’s biosimilar has one final shot to dethrone Humira

AbbVie’s last stand: How an Icelandic billionaire’s biosimilar has one final shot to dethrone Humira

Source: 
Endpoints
snippet: 

When AbbVie CEO Richard Gonzalez sat before the House Committee on Oversight last week, calmly fending off questions about his mega-blockbuster Humira and its fortress of patents, the fate of any competition entering the US market before 2023 seemed all but sealed.